Successful culture and selection of cytokine gene-modified human dermal fibroblasts for the biologic therapy of patients with cancer

Human Gene Therapy

Volumn 7, Issue 4, 1996, Pages 479-487

  Elder, Elaine M ^a   Lotze, Michael T ^a,b   Whiteside, Theresa L ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; INTERLEUKIN 4;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CLINICAL TRIAL; COLON CARCINOMA; FIBROBLAST CULTURE; GENE THERAPY; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MELANOMA; SKIN FIBROBLAST;

EID: 0030000507     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.1996.7.4-479     Document Type: Article

References (23)

1. AZZARONE, B., CHAPONNIER, C., KRIEF, P., MAREEL, M., SUAREZ, H., and MACIEIRA-COELHO, A. (1988). Human fibroblasts from cancer patients: lifespan and transformed phenotype in vitro and role of mesenchyme in vivo. Mutation Res. 199, 313-325.
2. COLOMBO, M.P., MODESTI, A., PARMIANI, G., and FORNI, G. (1992). Perspectives in cancer research: local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk. Cancer Res. 52, 4853-4857.
3. FOOD AND DRUG ADMINISTRATION. (1991). Points to Consider in Human Somatic Cell Therapy and Gene Therapy. (Center for Biologics Evaluation and Research, Rockville, MD).
4. FRIBERG, D., BRYANT, J., SHANNON, W., and WHITESIDE, T.L. (1994). In vitro cytokine production by normal human peripheral blood mononuclear cells as a measure of immunocompetence or the state of activation. Clin. Diag. Lab. Immunol. 1, 261-268.
5. GANSBACHER, B., ZIER, K., DANIELS, B., CRONIN, K., BANNERJI, R., and GILBOA, E. (1990). Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med. 172, 1217-1224.
6. GASTL, G., FINSTAD, C.L., GUARINI, A., BOSL, G., GILBOA, E., BANDER, N.H., and GANSBACHER, B. (1992). Retroviral vector-mediated lymphokine gene transfer into human renal cancer cells. Cancer Res. 52, 6229-6236.
7. GOLUMBEK, P.T., LAZENBY, A.J., LEVITSKY, H.I., JAFFEE, L.M., KARASUYAMA, H., BAKER, M., and PARDOLL, D.M. (1991). Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254, 713-716.
8. HUNT, J.D., PIPPIN, B.A., LANDRENEAU, R.J., JACOB, W.F., LOTZE, M.T., and SIEGFRIED, J.M. (1993). Transfer and expression of the human interleukin-4 gene in carcinoma and stromal cell lines derived from lung cancer patients. J. Immunother. 14, 314-321.
9. JAFFEE, E.M., DRANOFF, G., COHEN, L.K., HAUDA, K.M., CLIFT, S., MARSHALL, F.F., MULLIGAN, R.C., and PARDOLL, D.M. (1993). High efficiency gene transfer into primary human tumor expiants without cell selection. Cancer Res. 53, 2221-2226.
10. LOTZE, M.T., and RUBIN, J.T. (1994). Gene therapy of cancer: A pilot study of IL4-gene-modified fibroblasts admixed with autologous tumor to elicit an immune response. Hum. Gene Ther. 5, 41-55.
11. PARDOLL, D. (1992). New strategies for active immunotherapy with genetically engineered tumor cells. Curr. Opin. Immunol. 4, 619-623.
12. + lymphocyte-driven and eosinophil-mediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to release IL-4. J. Immunol. 153, 5659-5673.
13. PIPPIN, B.A., ROSENSTEIN, M., JACOB, W.F., CHIANG, Y., and LOTZE, M.T. (1994). Local IL-4 delivery enhances immunity reactivity to murine tumors: Gene therapy in combination with IL-2. Cancer Gene Ther. 1, 35-42.
14. SAITO, S., BANNERJI, R., GANSBACHER, B., ROSENTHAL, F.M., ROMANENKO, P., HESTON, W.D.W., FAIR, W.R., and GILBOA, E. (1994). Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines. Cancer Res. 54, 3516-3520.
15. SALLUSTO, R, and LANZAVECCHIA, A. (1994). Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J. Exp. Med. 179, 1109-1118.
16. SUMINAMI, Y., ELDER, E.M., LOTZE, M.T., and WHITESIDE, T.L. (1995). In situ IL4 gene expression in cancer patients treated with a genetically-modified tumor vaccine. J. Immunother. 17, 238-248.
17. TEPPER, R.I., and MULE, J.J. (1994). Experimental and clinical studies of cytokine-modified tumor cells. Hum. Gene Ther. 5, 153-164.
18. TEPPER, R.I., PATTENGALE, P.K., and LEDER, P. (1989). Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 57, 503-512.
19. UCHIYAMA, A., HOON, D.S.B., MORISAKI, T., KANEDA, Y., YUZUKI, D.H., and MORTON, D.L. (1993). Transfection of interleukin 2 gene into human melanoma cells augments cellular immune response. Cancer Res. 53, 949-952.
20. WHITESIDE, T.L., WORRALL, J.G., PRINCE, R.K., BUCKINGHAM, R.B., and RODNAN, G.P. (1985). Soluble mediators from mononuclear cells increase the synthesis of glycosaminoglycan by dermal fibroblast cultures derived from normal subjects and progressive systemic sclerosis patients. Arthritis Rheum. 28, 188-197.
21. YU, J.S., WEI, M.X., CHIOCCA, E.A., MARTUZA, R.L., and TEPPER, R.I. (1993). Treatment of glioma by engineered interleukin 4-secreting cells. Cancer Res. 53, 3125-3128.
22. ZALOOM, Y., and GALLAGHER, G. (1993). IL-2 inhibits the induction of systemic antitumor immunity by IL-4 in the peritumoral treatment of experimental melanoma. Anticancer Res. 13, 1081-1086.
23. ZITVOGEL, L., TAHARA, H., CAI, Q., STORKUS, W.J., MULLER, G., WOLF, S.F., GATELY, M., ROBBINS, P.D., and LOTZE, M.T. (1994). Construction and characterization of retroviral vectors expressing biologically active human interleukin-12. Hum. Gene Ther. 5, 1493-1506.